Cases of tuberculosis felt directly related to the use of TNF inhibitors (etanercept, infliximab, adalimumab) have been reported to the United States Food and Drug Administration as part of its voluntary post-marketing drug safety surveillance program. Despite more cases than expected, particularly associated with infliximab, this database is not organized in a way to provide accurate information about incidence rates of any infection in TNF inhibitor treated patients. Using a different data collection instrument, the National Data Bank for Rheumatic Diseases, Wolfe et al (Arthritis Rheum 50(2):372, 2004) examine the incidence of TB in patients with RA treated and untreated with Anti-TNF therapy. This data was first presented at the 2003 American College of Rheumatology Annual Scientific Meeting.
Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.
Use of this Site
All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.